Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-1959R in Healthy Participants
NCT06831812Phase 1Completed
- Sponsor
- Nuravax
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AV-1959R in Alzheimer's disease (AD) (4 arms), sponsored by Nuravax. Primary endpoint: Safety and Tolerability of AV-1959R Compared to Placebo at 26 weeks. Started Jun 2024; status: completed.
02
Drugs
AV-1959R
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06831812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06831812.